Frailty in multiple myeloma

Welcome to the third edition of the Sanofi 2024 newsletter! These newsletters, created by Sanofi, aim to provide education to healthcare providers in relevant topics in multiple myeloma (MM). This edition will provide an overview of frailty in MM, highlighting the need for clinical trials to further investigate outcomes in this population and the importance of robust frailty assessment methods to inform treatment decision-making.

In this issue:

• Introduction
• The impact of frailty
• Factors contributing to frailty
• Frailty assessment and limitations of current frailty scores
• Inclusion of frailty in clinical trials
• Summary